Rowell N P, Clark K
Department of Radiotherapy, Royal Marsden Hospital, Sutton, Surrey, U.K.
Radiother Oncol. 1990 Aug;18(4):293-8. doi: 10.1016/0167-8140(90)90109-a.
Cardiovascular responses are reported in 21 patients with carcinoma of the bronchus taking part in a study of tumour perfusion. There were eight slow and 12 fast acetylators; acetylator status was not determined in one patient with a history of sulphonamide allergy. Hydralazine dose ranged from 25 to 150 mg orally (equivalent to 0.37 to 2.86 mg/kg). Mean arterial blood pressure fell from 98 mmHg before hydralazine to 90 mmHg 60 min after hydralazine (p = 0.002) and mean cardiac output rose from 5.53 l/min to 7.75 l/min (p = 0.00005). Calculated total peripheral resistance fell by 30% (p = 0.0002). Falls in peripheral resistance per milligram hydralazine administered were greater in patients over 70 years of age. Acetylator status was a poor predictor of response. Side-effects were reported by eight patients and were related to the magnitude of fall in peripheral resistance (p = 0.0005) but not to falls in blood pressure (p = 0.12).
在参与一项肿瘤灌注研究的21例支气管癌患者中报告了心血管反应。其中有8例慢乙酰化者和12例快乙酰化者；1例有磺胺类药物过敏史的患者未确定乙酰化状态。肼屈嗪口服剂量为25至150毫克（相当于0.37至2.86毫克/千克）。平均动脉血压从服用肼屈嗪前的98毫米汞柱降至服用后60分钟时的90毫米汞柱（p = 0.002），平均心输出量从5.53升/分钟升至7.75升/分钟（p = 0.00005）。计算得出的总外周阻力下降了30%（p = 0.0002）。70岁以上患者每毫克肼屈嗪引起的外周阻力下降幅度更大。乙酰化状态对反应的预测效果不佳。8例患者报告了副作用，且副作用与外周阻力下降幅度有关（p = 0.0005），但与血压下降无关（p = 0.12）。
